Veterinary epidemic prevention medicine as well as preparation method and application thereof

Abstract

The invention discloses a veterinary epidemic prevention medicine as well as a preparation method and application thereof, and relates to the field of veterinary drug research and development and veterinary medicine, and the veterinary epidemic prevention medicine is prepared from the following components in parts by volume: 9.0-9.8 parts of Shuanghuanglian; 0.2 to 1.0 part of polyinosinic cell; through the molecular chaperone effect of the Shuanghuanglian and the polyinosinic-polycytidylic acid, the permeability and retention of the antiviral drug in myocardial tissues are remarkably improved, the technical bottleneck that a traditional drug is insufficient in myocardial virus load control is broken through, the damage of cytokine storm to myocardial cells is effectively inhibited while the antiviral immune response is enhanced, and the curative effect is good. The ratio of the Shuanghuanglian to the polyinosinic acid is optimized, the basic antiviral activity of the Shuanghuanglian is guaranteed, the immune regulation function of the polyinosinic acid is exerted with the minimum effective dose, the dose-dependent side effect is avoided, the medication process is simplified in clinical application, an innovative medicine combination with high efficiency, safety and economical efficiency is provided for the modern breeding industry, and the clinical application prospect is wide. And the method has remarkable industrial popularization value.

Description

Technical Field

[0001] The present invention relates to veterinary drug research and development and veterinary technology, and in particular to an veterinary epidemic prevention drug and a preparation method and application thereof. Background Art

[0002] Foot-and-mouth disease (FMD) is an acute, severe, zoonotic infectious disease caused by infection with the foot-and-mouth disease virus (FMDV). Myocarditis complications are the core pathological mechanism leading to high mortality in affected animals. FMDV belongs to the Picornaviridae family and has seven serotypes. There is no cross-protection between these serotypes, posing significant challenges to vaccine development and epidemic prevention and control. The disease primarily infects even-toed ungulates such as cattle, pigs, and sheep, and humans are also susceptible. The virus can spread through various pathways, including direct contact, airborne transmission, and waterborne transmission. Contaminated environments and objects can serve as sources of infection. FMD epidemics exhibit distinct seasonality, with peak incidence in winter and spring. However, the mobility of modern livestock farming has led to a continuous increase in the frequency and scope of outbreaks.

[0003] Traditional veterinary antiviral drugs face numerous technical bottlenecks when addressing foot-and-mouth disease and its myocarditis complications. First, the effects of a single ingredient are limited. While existing traditional Chinese medicine preparations, such as Shuanghuanglian, possess antiviral activity, they struggle to overcome the technical challenges of high viral loads in myocardial tissue and low efficiency in repairing damaged myocardial cells. Immune regulation conflicts with inflammatory storms, and existing immunopotentiators (such as poly I-C) are prone to inducing excessive immune responses when used alone, exacerbating myocardial inflammatory damage. Furthermore, existing compound medications lack a synergistic model for Shuanghuanglian and poly I-C, failing to maximize efficacy through interactions between their components. Summary of the Invention

[0004] The purpose of the present invention is to provide a veterinary epidemic prevention drug and its preparation method and application, so as to solve the problems of traditional veterinary antiviral drugs in the prior art in treating foot-and-mouth disease myocarditis, such as the limited efficacy of a single ingredient, the susceptibility of immunomodulators to inducing inflammatory storms, and the lack of synergistic effects.

[0005] In order to achieve the above object, the present invention provides the following technical solution: a veterinary epidemic prevention drug, comprising the following components in parts by volume:

[0006] Shuanghuanglian 9.0-9.8 parts;

[0007] Poly I-cell 0.2-1.0 copies.

[0008] Further, it is composed of the following components in parts by volume:

[0009] Shuanghuanglian 9.4 parts;

[0010] Poly I-cell 0.6 copies.

[0011] A method for preparing the above-mentioned veterinary epidemic prevention drug comprises the following steps:

[0012] S1. Prepare 9.0-9.8 parts by volume of Shuanghuanglian and 0.2-1.0 parts of poly I-cell;

[0013] S2. Mix the prepared Shuanghuanglian and poly I-cell under sterile conditions.

[0014] A use of the above-mentioned veterinary epidemic prevention drug in the preparation of a drug for treating foot-and-mouth disease and myocarditis caused by foot-and-mouth disease.

[0015] Compared with the existing technology, the veterinary epidemic prevention drug provided by the present invention, as well as its preparation method and application, significantly improves the permeability and retention of antiviral drugs in myocardial tissue through the molecular chaperone effect of Shuanghuanglian and poly I-cell, breaking through the technical bottleneck of traditional drugs in insufficient control of myocardial viral load. While enhancing the antiviral immune response, it effectively inhibits the damage of cytokine storm to myocardial cells.

[0016] By optimizing the ratio of Shuanghuanglian and poly ICP, while ensuring the basic antiviral activity of Shuanghuanglian, the immunomodulatory function of poly ICP is exerted at the minimum effective dose, avoiding dose-dependent side effects. In clinical applications, the medication process is simplified and the safety is greatly improved, providing the modern breeding industry with an innovative drug combination that is both efficient, safe and economical, and has significant industrial promotion value. BRIEF DESCRIPTION OF THE DRAWINGS

[0017] In order to more clearly illustrate the embodiments of the present application or the technical solutions in the prior art, the following briefly introduces the drawings required for use in the embodiments. Obviously, the drawings described below are only some embodiments described in the present invention. For ordinary technicians in this field, other drawings can also be obtained based on these drawings.

[0018] Figure 1 This is a flow chart of the preparation method of veterinary epidemic prevention drugs provided in an embodiment of the present invention. DETAILED DESCRIPTION

[0019] In order to make the above-mentioned objects, features and advantages of the present invention more obvious and easy to understand, the specific embodiments of the present invention are described in detail below.

[0020] In the following description, many specific details are set forth to facilitate a full understanding of the present invention. However, the present invention may also be implemented in other ways different from those described herein. Those skilled in the art may make similar generalizations without violating the connotation of the present invention. Therefore, the present invention is not limited to the specific embodiments disclosed below.

[0021] In addition, the experimental methods used in the following examples are all conventional methods unless otherwise specified, the materials and reagents used are all commercially available unless otherwise specified, and the equipment used in the experiments are all well known to those skilled in the art unless otherwise specified.

[0022] Example 1

[0023] A veterinary epidemic prevention drug, consisting of the following components:

[0024] Shuanghuanglian: Shuanghuanglian injection 9.4ml, composed of honeysuckle, scutellaria, and forsythia. Quality control: in compliance with the 2020 edition of the Veterinary Pharmacopoeia of the People's Republic of China, with baicalin content ≥35mg / ml (measured value: 41.2mg / ml);

[0025] Poly I:C: 0.6 ml of poly I:C solution, composition: polyinosinic-polycytidylic acid (Poly I:C); quality control: molecular weight 60-150 kDa, concentration 0.3 mg / ml (CAS 29422-25-3).

[0026] The preparation method comprises the following steps:

[0027] S1. Prepare 9.4 ml of Shuanghuanglian injection: obtain commercially available Shuanghuanglian injection that complies with the veterinary pharmacopoeia;

[0028] 0.6 ml of poly I-cell solution: Take sterile poly I-cell stock solution (concentration 1.0 mg / ml) and dilute it to 0.3 mg / ml with sterile saline;

[0029] S2. Mix the prepared Shuanghuanglian injection with the polyinosinic acid solution under sterile conditions to obtain the product.

[0030] The invention discloses an application of a veterinary epidemic prevention drug in the preparation of a drug for treating foot-and-mouth disease and myocarditis caused by foot-and-mouth disease.

[0031] Example 2

[0032] A veterinary epidemic prevention drug, consisting of the following components:

[0033] Shuanghuanglian: Shuanghuanglian injection 9.0ml, composed of honeysuckle, scutellaria, and forsythia. Quality control: in compliance with the 2020 edition of the Veterinary Pharmacopoeia of the People's Republic of China, with baicalin content ≥35mg / ml (measured value: 41.2mg / ml);

[0034] Poly I:C: 1.0 ml of poly I:C solution, composition: polyinosinic-polycytidylic acid (Poly I:C); quality control: molecular weight 60-150 kDa, concentration 0.3 mg / ml (CAS 29422-25-3).

[0035] The preparation method is the same as that in Example 1.

[0036] The invention discloses an application of a veterinary epidemic prevention drug in the preparation of a drug for treating foot-and-mouth disease and myocarditis caused by foot-and-mouth disease.

[0037] Example 3

[0038] A veterinary epidemic prevention drug, consisting of the following components:

[0039] Shuanghuanglian: Shuanghuanglian injection 9.8ml, ingredients include honeysuckle, scutellaria, and forsythia. Quality control: in compliance with the 2020 edition of the "Pharmacopoeia of the People's Republic of China", baicalin content ≥35mg / ml (measured value: 41.2mg / ml);

[0040] Poly I:C: 0.2 ml of poly I:C solution, composition: polyinosinic-polycytidylic acid (Poly I:C); quality control: molecular weight 60-150 kDa, concentration 0.3 mg / ml (CAS 29422-25-3).

[0041] The preparation method is the same as that in Example 1.

[0042] The invention discloses an application of a veterinary epidemic prevention drug in the preparation of a drug for treating foot-and-mouth disease and myocarditis caused by foot-and-mouth disease.

[0043] Application Experiment Examples

[0044] Comparative experiment on the treatment effect of foot-and-mouth disease myocarditis:

[0045] Experimental design:

[0046] 1. Experimental subjects:

[0047] 60 naturally infected FMD pigs (weighing 35-40 kg, with myocarditis confirmed by PCR);

[0048] Grouping: blank group (6 heads) + drug-treated group (6 heads in each group);

[0049] 2. Dosage regimen:

[0050]

[0051] Comparison of efficacy data (tested 24 hours after treatment):

[0052]

[0053] As can be seen from the above, Example 1 (9.4ml of Shuanghuanglian + 0.6ml of Poly Ion-Cell) showed overwhelming advantages in sudden death prevention, myocardial repair, virus clearance, and cure rate. Its unique ratio (94%:6%) was significantly superior to other ratios (90%:10% in Example 2 and 98%:2% in Example 3). This ratio maximizes the activation of antiviral immunity and inhibits the progression of myocarditis through the synergistic effect of Shuanghuanglian and Poly Ion-Cell, providing an optimal solution for the treatment of foot-and-mouth disease myocarditis.

[0054] The active ingredients in Shuanghuanglian (such as baicalin) produce a super synergistic effect with poly I-cell. Shuanghuanglian provides a protective barrier for the immune activation of poly I-cell, avoiding the inflammatory factor storm; at the same time, poly I-cell significantly enhances the antiviral penetration of Shuanghuanglian, enabling it to efficiently clear the foot-and-mouth disease virus in the myocardial tissue.

[0055] The above description is merely illustrative of certain exemplary embodiments of the present invention. It goes without saying that those skilled in the art will be able to modify the described embodiments in various ways without departing from the spirit and scope of the present invention. Therefore, the above drawings and description are illustrative in nature and should not be construed as limiting the scope of protection of the claims.

Claims

1. A veterinary epidemic prevention drug, characterized in that: It is composed of the following components in parts by volume: Shuanghuanglian 9.0-9.8 parts; Poly I-cell 0.2-1.0 copies.

2. A veterinary epidemic prevention drug according to claim 1, characterized in that: It is composed of the following components in parts by volume: 9.4 parts of Shuanghuanglian and 0.6 parts of Polyinosinic Acid.

3. A method for preparing the veterinary epidemic prevention drug according to any one of claims 1 to 2, characterized in that: The following steps are involved: S1. Prepare 9.0-9.8 parts by volume of Shuanghuanglian and 0.2-1.0 parts of poly I-cell; S2. Mix the prepared Shuanghuanglian and poly I-cell under sterile conditions.

4. Use of the veterinary epidemic prevention drug according to claim 1 or 2 in the preparation of a drug for treating foot-and-mouth disease and myocarditis caused by foot-and-mouth disease.

Images